, Volume 62, Supplement 2, pp 37–43 | Cite as

Use of Sustained-Release Bupropion in Specific Patient Populations for Smoking Cessation

Review Article


Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking. Bupropion SR has also been found to be a useful treatment of tobacco dependence in various special populations of smokers who often experience difficulty in overcoming tobacco addiction.

Point-prevalence quit rates at 6 months were higher in those treated with bupropion SR than in those receiving placebo in studies on smokers with chronic obstructive pulmonary disease (23% vs 16%) and in those with cardiovascular disease (34% vs 12%). Abstinence from smoking after treatment with bupropion SR was not affected by a history of major depression or alcoholism. Women treated with bupropion SR were just as likely as men to abstain from smoking. Approximately one-third of a study population who were initially unwilling or unable to quit smoking were able to reduce their smoking by 50% or more during therapy with bupropion SR; 14% of these went on to achieve abstinence.

Bupropion SR was well tolerated in these trials; importantly, it had no clinically significant effect on mean blood pressure in smokers, including those with hypertension, and attenuated the weight gain associated with smoking cessation, particularly in women.



S. Tonstad has undertaken research and consultancy for manufacturers of bupropion.


  1. 1.
    Hughes JR, Gulliver SB, Fenwick JW, et al. Smoking cessation self-quitters. Health Psychol 1992; 11(5): 331–4PubMedCrossRefGoogle Scholar
  2. 2.
    Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337(17): 1195–202PubMedCrossRefGoogle Scholar
  3. 3.
    Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340(9): 685–91PubMedCrossRefGoogle Scholar
  4. 4.
    Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. Ann Intern Med 2001; 35(6): 423–33Google Scholar
  5. 5.
    Rosenberg L, Kaufman DW, Helmrich SP, et al. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313(24): 1511–4PubMedCrossRefGoogle Scholar
  6. 6.
    Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161 (2Pt 1): 381–90PubMedGoogle Scholar
  7. 7.
    Tonstad S, Murphy M, Astbury C, et al. Effectiveness and tolerability of Zyban in smokers with cardiovascular disease -week 26 follow-up phase results [oral presentation]. European Society of Cardiology; 2001 Sep 1–5; Stockholm: abstract no.: 1460Google Scholar
  8. 8.
    Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571–5PubMedCrossRefGoogle Scholar
  9. 9.
    Olopade CO, Colah JJ, Wilken L, et al. Bupropion SR as an aid to smoking cessation in cigarette smokers receiving medicaid [abstract]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington (VA)Google Scholar
  10. 10.
    HatsukamiD, Rennard S, Malcolm R, et al. A multicentre study examining the effects of Zyban (bupropion SR) vs placebo as an aid to smoking reduction leading to cessation among smokers unwilling or unable to quit smoking [abstract]. Eighth Annual Conference of the Society for Research on Nicotine and Tobacco; 2002 Feb 22; Savannah (GA)Google Scholar
  11. 11.
    Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173–8PubMedCrossRefGoogle Scholar
  12. 12.
    Smith SS, Jorenby DE, Leischow SJ, et al. Targeting smokers at high risk for relapse: treating women and those with a history of depression [poster]. Eleventh World Conference on Tobacco OR Health; 2000 Aug 6–11; Chicago (IL)Google Scholar
  13. 13.
    Gonzales D, Bjornson WM, Buist AS, et al. Effects of gender relapse prevention in smokers treated with bupropion SR. Am J Prev Med 2002; 22(4): 234–9PubMedCrossRefGoogle Scholar
  14. 14.
    Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995; 25: 95–101PubMedCrossRefGoogle Scholar
  15. 15.
    Hall SM, Munoz RF, Reus VI, et al. Nicotine, negative affect, and depression. J Consult Clin Psychol 1993; 61(5): 761–7PubMedCrossRefGoogle Scholar
  16. 16.
    Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical Practice Guideline. Rockville (MD): US Department of Health and Human Services. Public Health Service, 2000 JunGoogle Scholar
  17. 17.
    Glassman AH, Covey LS, Stetner F, et al. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357(9272): 1929–32PubMedCrossRefGoogle Scholar
  18. 18.
    Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA 1988; 259: 2863–6PubMedCrossRefGoogle Scholar
  19. 19.
    Covey LS, Glassman AH, Statner F, et al. Effect of history of alcoholism or major depression on smoking cessation. Am J Psychiatry 1993; 150(10): 1546–7PubMedGoogle Scholar
  20. 20.
    Hurt RD, Dale LC, Offord KP, et al. Nicotine patch therapy for smoking cessation in recovering alchoholics. Addiction 1995; 90(11): 1541–6PubMedCrossRefGoogle Scholar
  21. 21.
    Windham GC, Elkin EP, Swan SH, et al. Cigarette smoking and effects on menstrual function. Obstet Gynecol 1999; 93(1): 59–65PubMedCrossRefGoogle Scholar
  22. 22.
    Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of lowdose oral contraceptives. N Engl J Med 1996; 335(1): 8–15PubMedCrossRefGoogle Scholar
  23. 23.
    Hollenbach KA, Barrett-Connor E, Edelstein SL, et al. Cigarette smoking and bone mineral density in older men and women. Am J Public Health 1993; 83(9): 1265–70PubMedCrossRefGoogle Scholar
  24. 24.
    Bjornson W, Rand C, Connett JE, et al. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health 1995; 85(2): 223–30PubMedCrossRefGoogle Scholar
  25. 25.
    Swan GE, Jack LM, Ward MM, et al. Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction 1997; 92(2): 207–17PubMedCrossRefGoogle Scholar
  26. 26.
    Wetter DW, Kenford SL, Smith SS, et al. Gender differences in smoking cessation. J Consult Clin Psychol 1999; 67(4): 555–62PubMedCrossRefGoogle Scholar
  27. 27.
    Royce JM, Corbett K, Sorensen G, et al. Gender, social pressure, and smoking cessations: the Community Intervention Trial for Smoking Cessation (COMMIT) at baseline. Soc Sci Med 1997; 44(3): 359–70PubMedCrossRefGoogle Scholar
  28. 28.
    Meyers AW, Klesges RC, Winders SE, et al. Are weight concerns predictive of smoking cessation?.: a prospective analysis. J Consult Clin Psychol 1997; 65(3): 448–52PubMedCrossRefGoogle Scholar
  29. 29.
    Scharf D, Shiffman S. Are women less able to quit smoking than men? A pooled analysis of published trials of bupropion SR [posterno. RP-82]. Eighth Annual Meeting of the Society for Research on Nicotine and Tobacco; 2002 Feb 20–23; Savannah (GA)Google Scholar
  30. 30.
    Rigotti NA, Thorndike AN, Niaura R, et al. Post-cessation weight gain in smokers taking bupropion: the effect of gender [abstract]. Sixth Annual Conference of the Society for Research on Nicotine and Tobacco; 2000 Feb 18–20; Arlington (VA)Google Scholar
  31. 31.
    Anonymous. Cigarette smoking among adults: United States, 1992, and changes in the definition of current cigarette smoking. Morb Mortal Wkly Rep 1994; 43: 342-6Google Scholar
  32. 32.
    Jarvis MJ. Patterns and predictors of smoking cessations in the general population. In: Bolliger CT, Fagerstom KO, editors. The tobacco epidemic. Basel: Karger, 1997: 151–64CrossRefGoogle Scholar
  33. 33.
    DiClemente CC, Prochaska JO, Fairhurst SK, et al. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 1991; 59(2): 295–304PubMedCrossRefGoogle Scholar
  34. 34.
    Cinciripini PM, Wetter DW, McClure JB. Scheduled reduced smoking: effects on smoking abstinence and potential mechanisms of action. Addict Behav 1997; 22(6): 759–67PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Department of Preventive CardiologyUllevål University HospitalOsloNorway

Personalised recommendations